SCHEMBL2634412

SCHEMBL2634412

CCOC(=O)NC(=O)N(S)c1ncccc1C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.45
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
MAPT P10636 1/20 0.43
MAPK1 P28482 1/20 0.43
CYP2C19 P33261 1/20 0.43
NPC1 O15118 4/20 0.40
RAB9A P51151 3/20 0.40
NLRP3 Q96P20 2/20 0.39
BRD4 O60885 1/20 0.39
CYP2C9 P11712 1/20 0.39
TSHR P16473 2/20 0.39
HTT P42858 2/20 0.37
KMT2A Q03164 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
GAA P10253 2/20 0.36
HPGD P15428 1/20 0.36
CRHBP P24387 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2634885 0.88 SMN1; SMN2 (0.44) SMN1; SMN2CYP1A2CYP3A4CYP2D6MAPT
SCHEMBL2251909 0.87 SMN1; SMN2 (0.43) SMN1; SMN2CYP1A2CYP3A4CYP2D6MAPT
SCHEMBL6877180 0.86 SMN1; SMN2 (0.43) SMN1; SMN2MAPTNPC1RAB9ABRD4
SCHEMBL2253741 0.81 SMN1; SMN2 (0.39) SMN1; SMN2CYP1A2MAPTNPC1CYP2C9
SCHEMBL2254282 0.78 CTSB (0.39) SMN1; SMN2CYP2C19NPC1KMT2AL3MBTL1
SCHEMBL28557994 0.77 GAA (0.45) SMN1; SMN2MAPTMAPK1NPC1RAB9A
SCHEMBL5473020 0.77 HSD17B1 (0.40) SMN1; SMN2CYP1A2CYP3A4CYP2D6MAPT
SCHEMBL12078604 0.75 SMN1; SMN2 (0.35) SMN1; SMN2BRD4CYP2C9
SCHEMBL2249665 0.75 ALDH1A1 (0.40) SMN1; SMN2CYP1A2MAPTMAPK1NPC1
SCHEMBL14742332 0.73 PLAU (0.42) SMN1; SMN2CYP1A2MAPTCYP2C19NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8633173-B2 Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives CEPHALON, INC (US) 2014-01-21 US disclosed
US-20130296312-A1 Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives CEPHALON, INC. 2013-11-07 US disclosed
US-8501936-B2 Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives CEPHALON, INC. (US) 2013-08-06 US disclosed
EP-2438066-A2 PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a]PYRIDINE DERIVATIVES Cephalon, Inc. (US) 2012-04-11 EP disclosed
US-20100311693-A1 Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives CEPHALON, INC. (US) 2010-12-09 US disclosed
WO-2010141796-A2 PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVES CEPHALON, INC. (US) 2010-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130296312-A1 Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives JAK2, JAK1, JAK3 SMN1; SMN2 3360/4885CYP1A2 1036/4885CYP3A4 2127/4885
US-20100311693-A1 Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives CCNA1, CCNY, RB1 SMN1; SMN2 3192/4885CYP1A2 612/4885CYP3A4 1762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.